Volume 17, Number 1—January 2011
Dispatch
Foreign Travel and Decreased Ciprofloxacin Susceptibility in Salmonella enterica Infections
Manar Al-Mashhadani, Robert Hewson, Roberto Vivancos, Alex Keenan, Nick J. Beeching, John Wain, and Christopher M. Parry
Table
Relationship between nontyphoidal Salmonella enterica serovar, phage type, nalidixic acid resistance, and history of foreign travel, Liverpool, UK, 2003–2009*
| Serovar |
Total no. (%) patient isolates |
No. (%) patients with foreign travel history |
No. (%) patients with nalidixic acid–resistant isolate |
No. (%) patients with foreign travel history and nalidixic acid–resistant isolate |
| All | 492 (100.0) | 110 (22.4) | 103 (20.9) | 35 (31.8) |
| Enteritidis PT1 | 53 (10.8) | 16 (30.2) | 36 (67.9) | 9 (56.3) |
| Enteritidis PT4 | 93 (18.9) | 12 (12.9) | 4 (4.3) | 2 (16.7) |
| Enteritidis PT8 | 43 (8.7) | 8 (18.6) | 1 (2.3) | 1 (12.5) |
| Enteritidis PT21 | 22 (4.5) | 5 (22.7) | 10 (45.4) | 1 (20.0) |
| Enteritidis (other PT) | 104 (21.1) | 13 (12.5) | 16 (15.4) | 3 (23.1) |
| Typhimurium | 44 (8.9) | 11 (25.0) | 3 (6.8) | 1 (9.1) |
| Newport | 14 (2.8) | 3 (21.4) | 8 (57.1) | 3 (100.0) |
| Virchow | 12 (2.4) | 9 (75.0) | 11 (91.7) | 8 (88.9) |
| Other | 107 (21.7) | 33 (30.8) | 14 (13.1) | 7 (21.2) |
*PT, phage type.
Page created: July 08, 2011
Page updated: July 08, 2011
Page reviewed: July 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.